QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer
Status:
Terminated
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
This is a randomized phase II multi-institution prospective open label study in which up to
90 subjects with metastatic, locally advanced unresectable or recurrent pancreatic cancer who
previously received treatment with chemotherapy with FOLFIRINOX or FOLFIRINOX-like regimen
will be enrolled into one of two arms:
A: NPC-1C with gemcitabine and nab-paclitaxel or B: gemcitabine and nab-paclitaxel